NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Leucine-rich repeat kinase 2 (LRRK2) has gone, in a little over 2 decades, from a novel gene linked to cases of Parkinson's disease (PD) in one family to being the main actionable target for PD therapeutics, with several clinical trials targeting it currently underway. While much remains to be understood about LRRK2-including, chiefly, why its increased activity is linked to PD-much has also been learned. One of the areas where our knowledge has increased exponentially in a very short time is the structural biology of LRRK2. The goal of this review is to provide a survey of the current landscape of LRRK2 structural biology with an emphasis on the functional insights that structures have provided.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.